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ABSTRACT
Background: Buprenorphine is a semisynthetic opioid agonist-antagonist that displays
antagonism at kappa receptors and partial agonist at mu receptors.1 Buprenorphine has the
unfortunate effect of interfering with the actions of opioids administered for medical
indications.2 When patients on buprenorphine present for surgery or procedures requiring
anesthesia, it can become a substantial challenge.2 Currently, there are no guidelines or checklists
that would help the anesthetist to provide adequate pain management for the OUD patient
population.
Objectives: (1) Understand the perioperative management of patients with opioid addiction on
buprenorphine. (2) Demonstrate increased knowledge and confidence in understanding the
challenges, pharmacokinetics, and pharmacodynamics of managing a patient on buprenorphine.
(3) Discuss and manage perioperative interventions of patients taking buprenorphine with opioid
addiction.
Methodology: The primary methodology of the proposed project was to administer an online
Zoom educational module to providers that focus on the perioperative management of patients
with OUD who take buprenorphine. The project was implemented by conducting an online preassessment test, zoom educational module, and a post-assessment test that assessed the
anesthesia providers' knowledge about managing a patient with OUD on buprenorphine during
the perioperative period. Pre-assessment and post-assessment testing were used to measure the
effects of the educational module. Statistical analysis was applied to assess the effectiveness of
the educational module.
Results: There was a total of five Certified Registered Nurse Anesthetists (CRNAs) that
participated in the quality improvement project. The results reflected an improvement in
knowledge based on the pre-test and post-test scores. Knowledge showed an average gain of
(25%). In addition, the post-test demonstrated that participants are most likely (n=4, 80%) or
somewhat likely (n=2, 20%) to implement a perioperative checklist for surgical patients with
opioid addiction taking buprenorphine.
Conclusion: An evidence-based educational module determined an increase in participants'
knowledge of managing surgical patients with OUD taking buprenorphine during the
perioperative period. There is no consensus on the management of buprenorphine; however, the
recommendation is to continue buprenorphine during the perioperative period.
Keywords: buprenorphine or naloxone or buprenorphine/naloxone, drug use or opioid use
disorder or opioid abuse, opioid replacement therapy
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BACKGROUND
Introduction
Buprenorphine is a semisynthetic opioid agonist-antagonist that displays antagonism at
kappa receptors and partial agonist at mu receptors.1 The peak-and-valley plasma effects seen
with shorter-acting opioids are minimized for patients on buprenorphine because of its long halflife.1,3 Additionally, the kappa antagonism of buprenorphine minimizes the euphoric and
psychotomimetic effects associated with opioid use.3 Buprenorphine has the unfortunate effect of
interfering with the actions of opioids administered for medical indications.2 When patients on
buprenorphine that present for surgery or procedures requiring anesthesia, it can become a
substantial challenge.2
Since 2002, buprenorphine has been used for addiction therapy, opioid detoxification,
and acute and chronic pain management.2 Buprenorphine has exceptional properties that make it
a reliable option for treating OUD and pain management. When comparing buprenorphine to a
similar drug such as methadone, buprenorphine has a lower risk for respiratory depression, fewer
withdrawal symptoms, sedative effects, and a lower risk of toxicity at high doses.2
Buprenorphine is available in two forms: alone with only buprenorphine (Probuphine®,
Sublocade™, Bunavail®) and in a mixture with the opioid receptor antagonist naloxone
(Suboxone®, Zubsolv®).3,4 Suboxone® is a sublingual formulation of buprenorphine and
naloxone, a designated treatment for patients with OUD. Buprenorphine also has off-label uses
that include management of opioid withdrawal and chronic pain.4 Buprenorphine's
comprehensive safety profile, and full agonist properties for analgesia have made it increasingly
popular for individuals with chronic pain and addiction.2 Buprenorphine precludes perioperative
issues the anesthetist may encounter when managing pain for the OUD surgical patient.
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Buprenorphine has been developed for patients with long-standing pain with OUD.5
There is an increasing number of individuals treated for chronic pain and illegal narcotic use,
which means anesthesia providers will begin to see more patients prescribed drugs such as
buprenorphine. Over three million people are on or have a history of being treated with
buprenorphine; this could be challenging for the anesthetist to provide acute pain management in
the operating room.5 Currently, there are no guidelines or checklists that would help the
anesthetist to provide adequate pain management for the OUD patient population.
Consequences of the problem
Patients on buprenorphine are often mismanaged in the operating room. There are no
perioperative guidelines or checklists provided to the anesthetist to manage the OUD patient
population. If patients with OUD are mismanaged, it can pose a significant risk to long-term
health, including the risk of relapsing.6 Patients that have a history of OUD or chronic pain
frequently have other comorbidities that lead to surgery.6 Often, anesthesia providers are
unaware of the special considerations necessary when a patient is on buprenorphine; this creates
uncertainty in managing the patient's pain intraoperatively.6
The goal of managing the OUD patient is to efficiently manage postoperative pain, to
improve patient satisfaction, surgical outcomes, and to reduce the cost of healthcare.2 Providing
effective postoperative pain management increases patient satisfaction, improves patient
outcomes, and lowers healthcare costs. The anesthetist is the common denominator in providing
care for the patient from the preoperative, intraoperative, and postoperative periods. Therefore,
the anesthetist should stay well-informed on how to manage patients on long-term opioid
therapy, such as buprenorphine, presenting for surgery. If the anesthesia provider is unaware of
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how to manage individuals on buprenorphine, it will decrease patient satisfaction, can cause the
patient to relapse, and increase healthcare costs.6
Knowledge gaps
The perioperative management of patients on buprenorphine therapy is not precise, and
there are no current guidelines or checklists on how to manage patients on buprenorphine.2
Currently, understanding the risks versus benefits of continuing or stopping buprenorphine
perioperatively is inadequate due to a lack of high-quality evidence.2 Many anesthesia providers
lack the knowledge and education about how to manage pain on the perioperative surgical setting
for patients on buprenorphine.6
Often there is a shared misperception about the stopping or continuing buprenorphine
during the perioperative period.5 Common barriers are due to the confusion about whether or not
to continue buprenorphine and need to take the following into consideration, adequate pain
control postoperatively, reduce opioid cravings, improvements of overall well-being, and
increased engagement in discharge planning.5 Amongst anesthesia providers, there is a lack of
knowledge required to manage pain in patients on buprenorphine.5 A strategic plan must be
developed for OUD patients to achieve adequate pain control. The development of guidelines
and a preoperative checklist can help the anesthetist create a plan of care for this patient
population.
Proposal solution
Formulation of guidelines and a checklist will guide the anesthetist to provide adequate
analgesia and anesthesia to patients on buprenorphine.6 Clinical practice guidelines (CPGs) and
checklists offer a way of bridging the gap between best practice, policy, and the patient's choice.
The Institute of Medicine (IOM) defines "CPGs as a statement that includes recommendations
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intended to optimize patient care that is informed by systematic reviews of evidence and an
assessment of the benefits and harms of alternative care options." 6 Providing guidelines to
anesthetists on how to care for patients on buprenorphine will help to improve overall outcomes
for OUD patients. Guidelines and a checklist will improve the effectiveness and quality of care,
decrease cost, and decrease variations in the clinical practice in managing patients on
buprenorphine.6
The following PICO was formulated: (P) For adult surgical patients on buprenorphine (I)
does the use of an evidence based preoperative checklist (C) compared to no checklist (O)
increase the CRNA's knowledge and confidence in understanding the challenges,
pharmacokinetics and pharmacodynamics of managing patients on buprenorphine?
METHODOLOGY
Information Sources and Search Strategy
A literature search was conducted to identify studies on patients taking buprenorphine
and undergoing a surgical procedure. To direct the search and format of the systematic review,
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist
was used.7 The importance of a systemic review relies on what was done, what was discovered,
and the clarity of the documentation, as well as the research.7 The PRISMA checklist ensures
that the systematic review will serve as a useful resource for clinicians.7
The search utilized Cochrane Database of Systematic Reviews, Medline (ProQuest),
Cumulative Index of Nursing and Allied Health Literature (CINAHL), and PubMed electronic
database. A PICO format question was used to help develop the keywords and concepts used to
search each electronic database. The search terminology included block terms for (buprenorphine
or naloxone or buprenorphine/naloxone), (drug use or opioid use disorder or opioid abuse)
(relapse), (opioid replacement therapy), (peri-operative or preoperative or post-operative terms or
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surgery). The literature search and screening methodology is outlined in Figure 1 in a PRISMA
flow diagram.7 As of 22 October 2020, the search was current. The Medline (ProQuest) database
yield 113 articles, CINAHL resulted in 142, and the PubMed database revealed 92 results. A
total of 347 articles were retrieved from all 3 databases. Duplicates were removed, leaving 172 to
be evaluated.

Identification
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Records identified through
database searching
(n = 347)

Additional records identified
through other sources
(n = 0)

Screening

Records after duplicates removed
(n =172)

Records screened
(n = 172)

Included

Eligibility

Full-text articles assessed
for eligibility
(n = 21)

Figure 1. PRISMA Flow Diagram

Studies included in
qualitative synthesis
(n = 15)

Records excluded
(n = 151)

Full-text articles
excluded, with reasons
(n = 6)
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Study Selection and Screening Method with Inclusion/Exclusion Criteria
The preliminary PICO question was used to determine appropriative article titles and
abstracts that were found. The search strategies were not limited by study type and level of
evidence. The retrieved citations were imported to Endnote and checked for duplicates. Full-text
screening was conducted on the 15 articles that were based on strict inclusion and exclusion
criteria.
The inclusion criteria included articles published in English, and articles published 2010
to present day, RCTs, observational studies including case-control studies and cohort studies, as
well as case series and CR. The inclusion criteria also included patients taking buprenorphine
for chronic pain or OUD. In any case in which buprenorphine was extended after 12 hour
postoperatively, it was known to be in the buprenorphine "continuous" group.8 Other information
on management classifications was obtained where possible, including:
1. Maintenance dosage and buprenorphine preparation
2. Reasons for the preo-perative use of buprenorphine
3. The mode of continuity or discontinuation depends on the author's proposed
management technique.
The exclusion criteria included studies where patients were administered buprenorphine
exclusively in the intraoperative or postoperative period. For all other inclusion and exclusion
criteria, refer to Table 1. OUD for the systemic review was defined as the misuse of prescribed
opioid medications or the use of illicitly obtained opioids.4 Chronic pain was defined as any pain
that lasts longer than three months.4
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Table 1. Inclusion and Exclusion Criteria
Inclusion
Population:
• OUD patients taking buprenorphine.
• Chronic pain patients taking buprenorphine
Intervention
• All studies involving the peri-operative
treatment of patients taking buprenorphine in
the preoperative period to manage OUD or
pain were included.
Outcomes:
• Qualified effectiveness of either continuing
buprenorphine or discontinuing
buprenorphine in the peri-operative period
and successful pain management.
• Pain control and patient-reported outcomes
were noted when available.
• Long-term follow-up, including information
about OUD relapse and chronic pain
statistics, were noted when presented.
Type of study:
• observational studies including case-control
studies and cohort studies, as well as case
series and CR.
• RCTs

Exclusion
Population:
• Non-OUD patients
• Non-surgical patients on
buprenorphine
Intervention:
• Any patients receiving
buprenorphine only
preoperative or
postoperative for pain
management.
Outcomes:
• Anything other than perioperative management for
patients taking
buprenorphine for OUD
or chronic pain
Type of study:
• Publication date pre-2010
• Dissertations/theses
• Questionnaire
• Animal studies

Collection, Analysis, and Data Items
A systematic method was used to extract the selected studies. The selected studies were
attentively evaluated using the Johns Hopkins research evidence appraisal tool.9 John Hopkins'
rating structure includes 5 levels of evidence. Level 1 involves RCTs and systematic review of
RCTs with or without meta-analysis.9 Due to the lack of high-quality evidence, only two RCT
(Level 1) was included within the quality improvement project. Level 2 includes quasiexperimental studies.9 Level 3 are nonexperimental studies and systematic reviews of a
combination of RCTs and quasi-experimental studies.9 Level 4 involves the opinions of
respected authorities and nationally recognized experts of scientific evidence.9 Level 5 includes
case reports, clinician experience, and literature reviews.9 John Hopkins also describes each
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evidence level as high, good, or low quality of evidence. 'High' quality consists of data that is
reliable, widespread, enough control, appropriate sample size for the form of analysis, and
definitive findings.9 If it has relatively precise results with a reasonable sample size, some
monitoring, and definite conclusions, an article gets a 'good' ranking.9 A 'poor' standard ranking
has no evidence with findings that are not accurate, insufficient sample size for the analysis, and
a conclusion that cannot be drawn.9
An evaluation table was made to summarize and categorize each study's characteristics;
refer to table 2. Each study was assigned a ranking based on the John Hopkins research
evaluation tool. The information obtained and evaluated from each article included: (1) study
type and sample size, (2) whether or not buprenorphine was continued or discontinued in the
peri-operative phase, (3) analgesic success, (4) success of deterrence against opioid abuse, and
(5) if guidelines were provided. The evaluation table's headers included the author and date, the
details collected, and the ratings based on the Johns Hopkins Research Evidence evaluation tool.9
Table 2. Summary of RCT, Observational Studies, and Case Reports

Author
(Year) &
Level of
Evidence
Anderson
et al.
(2018)
Level 1
Quality B

Indication
s for
Buprenorp
hine use

Study
type/
Sample
size

Was buprenorphine Analgesia
continued
success
perioperatively or
discontinued

Chronic
pain or
OUD

Systematic
review

Both options were
observed.

Pain was well
controlled in
patients who
continued
buprenorphine
perioperatively.
Poorly
controlled in
patients who
discontinued
buprenorphine
perioperatively.

Success
of
deterrenc
e against
opioid
abuse
Nonreported

Guidelines
provided

Suggested that
guidelines
would improve
management of
patients taking
buprenorphine.
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Jonan et
al.
(2018)

Chronic
pain or
OUD

Level 4
Quality A

Chern et
al.
(2013)

Chronic
pain

Level 5
Quality A

Vaginal
mesh
removal
and
cystoscopy
X2

Recommendations
for preoperative
management of
buprenorphine was
based on urgency
and type of surgical
procedure.

Poorly
controlled pain

Both methods were
conducted,

Buprenorphine
was
discontinued
five days before
surgery and the
patient was
switched to
hydromorphone
4 mg PO q4-6
hours. The
patient
experience
"unbearable"
pain 8/10.

Sample
Size: 1

Hansen et
al.
(2016)
Level 3
Quality B

Study
group
(patients
with a
history of
OUD)
compared
to a control
group
(patients

Total hip
(n = 8) and
knee (n =
9)
arthroplast
y,
continuing
Buprenorp
hine
/naloxone

Buprenorphine/nalox
one was continued in
the patients with a
history of OUD.

Patient
experience
poorly
controlled pain
when
buprenorphine
was continued
perioperatively.
There was no
significant
difference in
pain scores
between groups
studied

High risk
of a
relapse if
buprenorp
hine is
held for
an
extended
period
prior to
the
procedure
.
Nonreported

Yes

Relapse
rate of
heroin
addiction
has been
shown up
to 50%.

No

Yes

16
without a
history of
OUD)

Anderson
et al.
(2017)

Chronic
pain or
OUD

Level 3
Quality A

Kornfeld
et al.
(2010)

Chronic
pain or
OUD

Level 5
Quality A

Macintyr
et al.
(2013)
Level 4
Quality B

OUD

Five
patients
who
underwent
seven
major
surgical
procedures
including
colectomy,
total knee
replacemen
t, small
bowel
resection
and
mastectom
y.
22 patients,
Any
surgery,
taking
buprenorph
ine or
methadone.

Elective versus
urgent/emergent
surgery determined if
buprenorphine was
continued or
discontinued
perioperatively.

Pain control
was adequate
when
comparing
management of
patients on
Buprenorphine
for elective
versus
urgent/emergent
surgery

There were no
interruptions of daily
buprenorphine
therapy.

All had
successful
analgesia
reported.

Partial:
buprenorphine
continued POD 0 in
14/22 patients (64%)
and POD 1 in 11/22
patients (50%).

Well controlled
pain, no
significant
differences
between groups
or between
continuation

Suggests
abrupt
discontinu
ation of
buprenorp
hine in
highly
stressful
preoperati
ve period
increases
risk for
relapsing
Nonreported

Yes (refer to
figures 1 and 2)

Nonreported

No, suggested
continuing
buprenorphine
perioperatively

No, however,
emphasized the
need for perioperative
guidelines.
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without
stopping.
Quaye et
al.
(2020)

OUD

Level 2
Quality B

Hassamal
et al.
(2017)

OUD

Level 5
Quality A
Huang et
al.
(2014)
Level 5
Quality B
Martine et
al.
(2019)
Level 5
Quality A

Chronic
pain

OUD

55 patients,
who had
surgery
from
MarchOctober
2018.
Minor
procedures
such as
colonoscop
ies and
endoscopie
s were
excluded.
Tricuspid
and Aortic
valve
repair
Sample
Size: 1
Clagett
window
closure
Sample
size: 1
Various
surgeries
and type of
anesthesia
included in
the study.
Sample
size: 32

Partial: 38 continued
buprenorphine versus
17 held
buprenorphine

The number of
opioid
prescriptions
dispensed was
significantly
higher with
buprenorphine
discontinuation.
PACU pain
scores were
higher with
buprenorphine
discontinuation.

Discontinued and
Well controlled
restarted
pain
postoperatively;
timing of change was
not reported.

Continued
buprenorphine by
50% postoperatively,
with subsequent
tapering to 0 mg
before discharge.
19 patients continued
sublingualbuprenorphine, 13
discontinued
sublingualbuprenorphine 1 to
30 days before
surgery.

Nonreported

No, suggest
continuing
buprenorphine
perioperatively

Six
No
months
after
surgery
refrained
from
opioids
Pain was poorly Abstained No
controlled;
from
Improved after
opioids at
postoperative
three
decrease
week
follow-up
patients who
The use of No
received longopioids
term treatment
increased
with sublingual- substantia
buprenorphine
lly after
had high opioid discharge
requirements
from the
through POD1, PACU,
regardless
and by 24
of type of
hours
anesthesia used after
or whether
PACU
sublingualdischarge,
buprenorphine
no
was
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preoperatively
continued or
discontinued.

Goul et al.
(2019)

Chronic
pain or
OUD

Level 4
Quality A
Hoflich et
al.
(2012)

OUD

Level 2
Quality B

Scholzen
et al.
(2019)
Level 5
Quality B

OUD or
Chronic
Pain

difference
s in opioid
requireme
nts were
noted
between
patients
who
underwent
surgical
procedure
s with
general
anesthesia
only
versus
combined
general/re
gional
anesthesia
.

Recommendations to
continue
buprenorphine in the
peri-operative
period.
37 + 80
Continued
controls;
perioperatively
(three
females
had a
second
child and
switched to
the
opposite
group,
totaling 40
cases)
Continue
perioperatively for
minor elective
surgeries.

Non-released

Nonreleased

Pain well
controlled.

Nonreleased

Yes, several
guidelines from
difference
authors were
included in the
article.
No

Suggests will
improve pain
management
for patients on
Buprenorphine.
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Meyer et
al.
(2010)

OUD

Level 2
Quality B

Li et al
(2020)

Discontinue
buprenorphine
postoperatively for
emergent surgery.
Continued
perioperatively

Vaginal (n
= 44) and
Cesarean
(n = 19)
delivery
taking
buprenorph
ine
50 trial
Compared continued,
patients
tapered, and
discontinued

Retrospect
ive Cohort
Study

Fiellin et al OUD
(2014)
RCT

113 patient
who were
studied
over an 18
week
period

The study consisted
of introduction and
maintenance of
buprenorphine
therapy for patients
with OUD

Pain was well
controlled,
Significantly
higher pain
scores in study
group versus
controls
postpartum
Results
determined
continue
buprenorphine
in the
perioperative
period
whenever
possible

Nonreleased

No

Nonreleased

No

Patients in
the taper
group
reported
more days
per week
of illicit
opioid use
than those
in the
maintenan
ce group
once they
were no
longer
receiving
buprenorp
hine.

No:
The RCT did
not consider
surgical
patients on
buprenorphine,
however, the
findings
concluded that
tapering is less
efficacious than
ongoing
maintenance
treatment in
patients with
OUD who
receive
buprenorphine
therapy.
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RESULTS
Analgesia Success
Chern et al conducted a case report in 2013 on a 37-year-old woman, ASA II, 170 cm, 88
kg, with chronic pelvic pain on buprenorphine, 8 mg sublingual every 8 hours, lorazepam 1 mg
every 6 hours, and zolpidem 10 mg at bedtime.10 The patient underwent two separate surgeries to
remove a vaginal mesh with two different pain management regimens who was on
buprenorphine for chronic pain management.10 For the first surgery, the patient continued
buprenorphine at 8 mg sublingual every 8 hours. A full opioid receptor agonist was used to
control postoperative pain. However, during the postoperative phase, the patient complained of
inadequate pain management. Buprenorphine was switched to a full opioid agonist five days
before the second surgery. Postoperative pain was managed with full opioid receptor agonists.
Despite significantly elevated doses of opioids, the patient again reported suboptimal pain
management. The patient was in severe pain in the postoperative period when buprenorphine was
continued during the perioperative period. When the patient withheld buprenorphine 5 days prior
to the second surgery, the patient reported suboptimal pain control in the postoperative period.
The case study highlights the challenge of pain control in perioperative patients on chronic
buprenorphine and emphasizes the need for additional investigation.
Li et al conducted a retrospective cohort study of surgical patients on buprenorphine
whose baseline dose had been preoperatively continued, tapered, or discontinued.11 The sample
size included 1200 patients on buprenorphine; out of the 1200 patients, 121 had surgery. A total
of 50 were admitted and included in the study. Charts of patients on buprenorphine were
reviewed who had received elective surgery at Stanford Healthcare from January 1, 2013, to June
30, 2016.11 Out of 50 trial patients 21, 42 percent, were on transdermal buprenorphine, 13
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patients were continued on the baseline buprenorphine dosage, seven were discontinued, and one
was tapered. In the remaining 29 patients, 58 percent, on an SL buprenorphine, 15 patients had
their dose continued, six patients had their dose tapered, and eight patients had their dose
discontinued.11 The primary outcome of interest was the change in pain score, defined as mean
postoperative pain score and preoperative pain score.11 The continuity of transdermal
buprenorphine during periodical procedures resulted in comparatively smaller post-operative
improvements in pain score, 0.606±0.878, relative to discontinuation, 4.83±1.23, P=0.012.11 In
patients taking SL buprenorphine, there was no statistically significant difference in the change
in pain score between those who were tapered to a nonzero dose versus discontinued, P=0.55.11
The continuation of SL buprenorphine resulted in fewer non-buprenorphine scheduled opioid
prescriptions than its taper or discontinuation, P=0.028.11 As pain is a subjective experience, the
primary outcome measured were the change in pain score per patient via the self-reported
numerical pain rating scale of a score from zero to ten.11 The preoperative score was collected
on the day of the procedure in the preoperative area whereas postoperative scores were collected
every 4 to 6 hours up to 24 hours after the procedure as a part of the vital sign checks for
medication administration.11 In conclusion, postoperative pain scores were improved in patients
whose transdermal buprenorphine had been continued perioperatively and lower morphine
milligram equivalents (MME) in scheduled opioid prescriptions for patients whose SL
buprenorphine had been continued perioperatively.11
Fiellin et al conducted a single site, RCT, from February 2009 through February 2013.
The RCT included 113 patients who were studied over 18 weeks.12 The study consisted of
introducing and maintaining buprenorphine therapy for patients with OUD. Of the 113 patients
who were randomized to the taper, n= 57, and maintenance, n= 56.12 Patients in the taper group
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reported more days per week of illicit opioid use than those in the maintenance group once they
were no longer receiving buprenorphine. Patients in the taper group were less likely to complete
the trial, P < .001.12 Sixteen patients in the taper group reinitiated buprenorphine treatment after
the taper owing to relapse. The RCT did not consider surgical patients on buprenorphine.
However, the findings concluded that tapering is less productive than ongoing maintenance
treatment in patients with OUD who receive buprenorphine therapy.
Hansen et al conducted a prospective matched cohort study in 2016 to compare clinical
outcomes of patients undergoing elective total knee arthroplasty (TJA) while being treated with
buprenorphine for OUD versus patients without OUD.13 Data collected was from electronic
medical records. Perioperative data were retrospectively obtained from patient charts.13
Postoperative functional outcomes were prospectively collected at follow-up visits. The study
group included 17 TJA patients, eight underwent total hip arthroplasty, and nine underwent total
knee arthroplasty. Seventeen of the study group patients took buprenorphine, and 35 matched
controls were identified.13 A change in morphine dosing at the time of discharge decreased in the
study group, -203.5, and increased in the control group, 84.3.13 The study showed statistically
significantly higher amounts of MME and referrals to the inpatient acute pain service in the
buprenorphine/naloxone therapy patients than matched controls.13 Nine patients in the study
group were referred to the pain service for stubborn pain compared to one patient in the control
group, P < .05.13 Study group patients received an MME dose of opioids that were roughly 8fold higher than that of the control group patients.13 Study group patients were prescribed 793
MME on narcotics per 24-hour period, range,120-1920, compared with 109 MME, range, 45-210
in the control group, P ¼ 1.4 _ 10_9.13 There were no significant differences in mean pain, 87.6
for the study group versus 84.4 for controls. There was no significant difference in pain scores
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observed at one year, 2.8 for the study group versus 2.1 for controls.13 Overall, patients who used
buprenorphine/naloxone preoperatively and underwent a TJA had similar clinical experiences to
the control group concerning the length of stay, functional outcomes, and complications.13
Macintyre et al performed a retrospective cohort study including data collected from 51
patients. Out of the 51 patients, 29 were taking methadone and 22 buprenorphine.14 The study
showed no difference in patient-controlled analgesia (PCA) morphine equivalents or pain scores
when comparing perioperative continuation versus cessation of buprenorphine.14 There was no
significant difference in days requiring acute pain service or PCA. The study showed higher
sedation rates in buprenorphine continued patients, but this did not correlate with lower
respiratory rates. However, the continuation of buprenorphine in this study was inconsistent with
14 out of 22 continuing on the day of surgery and 11 out of 22 continuing on post-operative day
(POD) one.14 Patients on buprenorphine who were not given buprenorphine the day after surgery
had significantly higher, P=0.02, PCA requirements in the first 24 hours after surgery, compared
with those who were given the usual dose.14 The study concluded that PCA opioid requirements
were less in patients who continued buprenorphine perioperatively than those whose regular dose
of buprenorphine was discontinued.14 Therefore, the study suggested buprenorphine should not
be withheld in patients undergoing surgery. The administration of buprenorphine reduces the
amount of PCA opioids required in order to achieve the same degree of pain relief.
A retrospective observational study was performed by Quaye et al on surgical patients
taking buprenorphine from March 2018 to October 2018. Emergency cases and minor
procedures, such as endoscopies and colonoscopies, were excluded from the analysis.15
Postoperative outpatient opioid dispensing and post-anesthesia care unit (PACU) pain scores
were compared in patients where buprenorphine was continued or held perioperatively.15 The
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study included 55 patients, 38 continued buprenorphine versus 17 held buprenorphine. There was
no difference in postoperative buprenorphine treatment adherence, 91% continued versus 88%
held, P=0.324.15 The number of opioid prescriptions dispensed was significantly higher with
buprenorphine discontinuation, 53% continued versus 82% held, P <0.011, as was MME
dispensed, mean of 229 continued versus mean of 521 held, P <0.033.15 PACU pain scores were
higher with buprenorphine discontinuation, mean 2.9 continued versus mean 7.6 held, P<0.001.15
Patients who continued buprenorphine had a significant reduction in opioid prescriptions filled
and PACU pain scores in patients than patients who held buprenorphine perioperatively.15
Evidence was provided to support that buprenorphine can be continued perioperatively and that
continuation is associated with decreased postoperative pain and decreased outpatient opioid
dispensing.15 The results contribute to the existing literature supporting the perioperative
continuation of buprenorphine.15
An RCT conducted by Höflich et al in 2011 compared parturient patients on
buprenorphine or methadone.16 The RCT included 40 pregnancies of 37 with OUD. These
patients participated in the Maternal Opioid Treatment: Human Experimental Research
(MOTHER) study.16 The retrospective investigation used data collected as part of the MOTHER
trial, focused on associated analgesic medication, including buprenorphine, administered during
and after delivery.16 The comparison group included 80 nonopioid dependent women delivered
in the same period as the opioid-dependent females. Participants were randomized to one of two
treatment groups, buprenorphine or methadone.16 Levels of the double-blind, double-dummy
medication were adjusted as required with a maximum level of 32 mg buprenorphine and 140
mg methadone.16 Following cesarean section opioid maintained women received significantly
less opioid analgesics, day 0: P = 0.038; day 1: P = 0.020; however, on day 3 a trend toward a

25
significant difference in the frequency of non-steroidal anti-inflammatory drug (NSAID)
application was revealed, P= 0.089.16 The study also showed that the rates of Cesarean delivery
were higher in methadone continued patients 68.4%, than buprenorphine continued patients
31.8%, although this result was not statistically significant. Pain scores and relapse rates were
not reported.16
Martin et al conducted a case series on adult surgical patients from December 31, 2004,
to January 1, 2016, who received SL-buprenorphine within 30 days before procedures performed
with general, regional, or combined general/regional anesthesia.1 Opioid use during the
procedure was recorded in the PACU and during the 24 hours following PACU discharge.1
Opioid use was examined in those who continued SL-buprenorphine until the day of surgery
compared to those who preoperatively discontinued SL-buprenorphine.1 The sample size
included thirty-two patients who underwent surgery while being treated with SLbuprenorphine.1 Three patients had regional anesthesia only, and opioid requirements were case
dependent.1 Requirements were minimal for creation of an arteriovenous fistula and high
following knee replacement and cesarean section.1 Twelve patients received combined general
and regional anesthesia, and 17 received general anesthesia only. Intraoperative and PACU
opioid use in these 2 groups were not significantly different, P = .10 and P = .93, respectively.1
Opioid requirements were analyzed by using log transformation and compared groups with the
2-sample t-test.1 All tests were 2-sided, and P < .05 was considered significant. Analyses were
performed with statistical software.1 The main finding was that patients who received long-term
treatment with SL-buprenorphine had high opioid requirements through POD1, regardless of the
type of anesthesia used or whether SL-buprenorphine was preoperatively continued or
discontinued.1 In both groups opioid use increased after discharge from the PACU, and remained
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comparable between the general and combined general and regional group through the first 24 h
after PACU discharge, P = .78.1 Although median 24 hour opioid doses were higher among
patients who discontinued SL- buprenorphine, the difference was not statistically significant in
the general anesthesia.1 Regardless of the type of anesthesia used, physicians treating patients
with SL-buprenorphine must be prepared to administer large doses of opioids during the early
postoperative period.1 No difference in opioid requirements was noted between patients who
perioperatively stopped SL-buprenorphine versus those who continued SL-buprenorphine.1
Kornfeld et al conducted a case series extracted from hospital and clinic charts with
patient consents in 2010. The case series included five patients who underwent seven major
surgical procedures, including colectomy, total knee replacement, small bowel resection, and
mastectomy.17 The case series included a 60-year-old male diagnosed with a hepatic flexure
carcinoma who underwent a right colectomy and cholecystectomy; due to obesity, the patient
experienced prolonged intubation.17 Postoperative analgesia included an epidural containing
morphine and an IV PCA, containing morphine, with doses at the high end of 27 mg/day
gradually reduced to 6 mg/day before discharge.17 The patient's dose of sublingual
buprenorphine was increased to 32 mg/day during the hospitalization.17 After being extubated,
the patient reported that pain was well controlled throughout the remainder of the hospitalization.
The patient was discharged on the increased dose of buprenorphine.
The case series included a 43-year-old male who underwent a right total knee
replacement. Postoperative analgesia was provided by epidural morphine and bupivacaine, IV
and oral hydromorphone, ketamine, sustained-release, and immediate-release oxycodone, and
sublingual buprenorphine. The epidural morphine was limited to a single dose of 0.2 mg, given
in the recovery room, and epidural bupivacaine was maintained for 48 hours. IV hydromorphone
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was provided on POD 1 to 3 at an average dose of less than 1 mg/hour.17 Oral hydromorphone
and oxycodone were introduced on POD 2 and 3, sublingual buprenorphine was continued
during the hospital stay, and the patient was discharged on 16 mg of buprenorphine and on oral
hydromorphone for breakthrough pain.17 Throughout the hospital stay, the pain and orthopedic
services reported excellent analgesia.
The same patient, 2 years later, underwent a left total knee replacement. The patient
postoperative pain management included epidural opioids and bupivacaine, IV and oral opioids,
and IV and oral ketamine. Epidural hydromorphone averaged 7 mg per day for the first 2 days,
after which the epidural was discontinued. Epidural bupivacaine was also given during this
timeframe, and additional epidural fentanyl was given as a PCA, averaging 70 mg/day.17 On the
day of surgery, the patient received 5 mg IV morphine. After the epidural was discontinued, oral
opioids, both short and long-acting, were provided at low dosages. Ketamine was given IV both
intra-operatively and later on surgery and was continued orally during POD 1 to 3 before
discharge.17 Pain was well managed with this regimen. In this case, SL-buprenorphine was not
given during this brief hospitalization but was restarted without difficulty at discharge at the
preoperative dose.
The case series included a 60-year-old male who was admitted for surgery with a small
bowel stricture with a peritoneal mass. A malignancy was removed.17 The surgery was
uneventful. The pain was easily managed in the recovery room and throughout the postoperative
period with uniformly favorable pain ratings on POD 1 to 4. Full agonist opioids were used
without difficulty at conventional doses. For example, fentanyl 150 mg was given
intraoperatively, and hydromorphone 1 mg was used in the recovery room. An epidural catheter
delivered bupivacaine and hydromorphone until POD 3, and an average of 0.2mg per hour of
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epidural hydromorphone was infused. PCA IV hydromorphone was also used through POD 4
and averaged between 5 and 10 mg per day. Parenteral buprenorphine was restarted on POD 3
without difficulty, and the patient was discharged on sublingual buprenorphine at his
preoperative dose.17
The case series included a 42-year-old female diagnosed with ductal carcinoma in situ of
the breast underwent bilateral subcutaneous mastectomy with reconstruction and implantation of
tissue expanders. The patient was maintained on 2 mg of sublingual buprenorphine throughout
the hospitalization. Postoperatively, the patient had an IV PCA containing hydromorphone
averaging 26 mg/day, discontinued on POD 2.17 The patient required both substantial doses of
oral hydromorphone and additional IV hydromorphone on POD 2. Pain scores were higher in
this case but responded well to the hydromorphone. The patient was discharged on SLbuprenorphine at the preoperative dose and on oral hydromorphone for breakthrough pain. The
same patient, 8 months later, underwent removal of bilateral tissue expanders with subsequent
placement of implants. The patient received 350 mg fentanyl intraoperatively. On the day of
surgery, the patient received 4 mg of sublingual buprenorphine, 5.4 mg of IV hydromorphone,
and 16 mg of oral hydromorphone. The pain was well controlled.17 Before discharge midday on
POD 1, the patient received 6 mg of hydromorphone orally and 2 mg buprenorphine
sublingually. The patient was discharged on the day after surgery. The patient was discharged on
SL-buprenorphine at the preoperative dose and on oral hydromorphone for breakthrough pain.
The case series included a 58-year-old male with a significant history of back pain and
chronic pain syndrome, underwent surgical removal of two X-Stop spacer devices from his
lumbar spine, inserted two years previously.17 The current procedure also involved lumbar
decompression at two levels. Intra-operatively, the patient received 600 mg of fentanyl, and in
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the recovery room, he received an additional 200 mg of fentanyl IV and 4 mg of IV
hydromorphone. On POD 1, the patient received 28 mg of oral hydromorphone and was
discharged on the morning of POD 2 with a reduced need for hydromorphone for breakthrough
pain on his preoperative dose of sublingual buprenorphine. Reported pain control was excellent,
and he progressed to physical therapy.17
In conclusion, all five patients were stabilized on SL-buprenorphine for at least one year
before any significant surgeries. Of the five patients and seven major surgeries, there were no
significant adverse effects, and all had successful analgesia reported. Intraoperative medication
reported were opioids, ketamine, and buprenorphine. All patients underwent surgery without
interruption of buprenorphine therapy. The case series supported the practice of maintaining
stable buprenorphine dosing for patients who require major surgery. Patients taking
buprenorphine, 2-24 mg/day, reported good postoperative pain was obtained by using full
agonist opioids.17
Perioperative management of Patients using Buprenorphine
Goel et al conducted an expert consensus Delphi-based survey in 2019. The Delphi based
survey technique included the following criteria: specifying the need for perioperative guidelines
for patients on buprenorphine and offer a set of recommendations for the perioperative
management of patients taking buprenorphine8. Goel et al developed a clinical practice advisory
22-step checklist recommended by the essential reporting items for practice guidelines in the
healthcare (RIGHT) group.8 The practice advisory's principal recommendation is to continue
buprenorphine therapy in the perioperative period. Rarely the dose of buprenorphine is reduced
regardless of indication or formulation.8 If analgesia is inadequate after optimizing adjunct
analgesic therapies, the article recommends initiating a full mu agonist while continuing the
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same buprenorphine dose.8 A systematic review of preoperative buprenorphine management
concluded that more evidence is required.8 There are multiple case reports and observational
studies. However, there is a lack of high-quality evidence in buprenorphine-maintained patients
using increased doses of opioids.
Lembke et al wrote an editorial in 2019 which looked at maintaining buprenorphine
through the perioperative period in patients being treated for OUD. Maintain buprenorphine in
patients with OUD avoids that risk of relapse and unwarranted burden on the health care system
and promotes safety, adherence, and continuity of care. Lembke et al viewed discontinuing
buprenorphine before surgery in patients with opioid use disorder introduces unnecessary risk for
four reasons. One of the risks expressed that buprenorphine discontinuation introduces a surgical
delay to allow adequate time to taper, require more clinic visits and care coordination between
multiple providers, and burden patients with additional preoperative instructions and tasks.18 The
second risk explained that after surgery, re-introduction of buprenorphine would be physically
painful and medically destabilizing for patients because the patient then undergoes an active
period of opioid withdrawal before buprenorphine can be restarted.18 The third risked described
that re-starting buprenorphine, particularly in the outpatient setting, is logistically complicated.
The patient is at risk for potentially discontinuing care, especially when multiple prescribers are
involved.18 The last risk explained that patients on buprenorphine for OUD are at increased risk
of relapse to opioid misuse and accidental overdose when buprenorphine is discontinued. The
patient may experience an opioid deficit while simultaneously gaining access to a new supply of
full-opioid agonists.18 Lembke et al suggest that patients taking 12mg or less of buprenorphine
daily maintain this dose unchanged, and patients on higher daily doses of buprenorphine (more
than 12 mg) taper to 12mg two to three days before surgery.18 The recommendation to taper

31
patients, when possible, down to 12mg buprenorphine is based on studies of receptor occupancy
and clinical experience.18
Figure 2. Lembke Guidelines for Surgical Patients Taking Buprenorphine.18
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Anderson et al conducted an observational study that included a review of case reports.4
Perioperative guidelines for surgical patients taking buprenorphine were developed in the study.
Anderson et al included the University of Michigan Health System protocol that is based on
clinical experience, published reports, and pharmacology. The protocol is intended to give the
patients, surgeons, nurses, and anesthetist guidance and expectations.4 Perioperatively, nonopioid
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analgesic strategies should be maximized. Inadequate pain management in patients taking
buprenorphine can lead to significant postoperative pain and prolong hospital stay. The authors
concluded that buprenorphine could be continued perioperatively, and co-administered opioid
agonists can efficiently treat acute pain.4 Below in figure 3 are the guidelines Anderson et al
published.
Figure 3. Anderson Guidelines for Managing Patients Taking buprenorphine.4

Scholzen et al outlined the options for perioperative management of patients taking
buprenorphine with OUD in 2019.19 Scholzen et al concluded that patients undergoing surgical
procedures expected to result in minimal postoperative pain are treated with the continuation of
buprenorphine therapy.19 For elective surgical procedures expected to result in moderate to
severe postoperative pain, the protocol suggests transitioning buprenorphine therapy to a shortacting full opioid agonist.19 When patients consuming buprenorphine present for emergent
surgery, the buprenorphine should be discontinued after surgery, and a multimodal regimen
should be implemented. Medication-assisted treatment (MAT) has emerged as an option to
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decrease the incidence of OUD and relapse prevention.19 MAT includes the administration of
medications such as buprenorphine. Scholzen developed a table that had the pharmacological
approach to perioperative management of the patients with MAT for OUD who are taking
buprenorphine.
Table 3. Scholzen Pharmacologic Management of Patients with OUD.19

Preoperative
• Acetaminopinen
PO
• NSAIDs PO
• Gabapentinoids
• Regional anthesia

Intraoperative
• Acetaminophen IV
• NSIADs IV
• Ketamine
• Magnesium
• Alpha-2 agonist
• Lidocaine
• Dexamethasone
• Esmolol
• Regional aneshesia
• Opioids

Postoperative
• Acetaminophen
PO/IV
• NSAIDs PO/IV
• Gabapentinoids
• Ketamine
• Lidocaine
• Alpha-2 agonist
• Capsaicin
• Opioids
PO/IV/PCA

Meyer et al conducted a case study that included sixty-three women treated with
buprenorphine for OUD.20 The patients were followed during the intrapartum and postpartum
period to determine pain differences in patients who do not take buprenorphine. Out of the sixtythree patients, 44 had a vaginal birth and 19 had a cesarean; the patients were matched to control
women.20 Analgesic medication and pain scores on a scale from 0 to 10 were extracted from the
medical record.20 Women maintained on buprenorphine during pregnancy required 50% more
opioid analgesic medication following cesarean delivery compared to control women.20 Opioid
use following vaginal birth was modest in both groups. Pain scores were consistently higher for
women maintained on buprenorphine following delivery from either route. During labor, women
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who continued buprenorphine had significant pain relief following regional analgesia initiation.20
Pain scores following vaginal birth were elevated in women maintained on buprenorphine, with
no difference in the amount or frequency of opioid use, P = 0.45. Following cesarean delivery,
women maintained on buprenorphine had higher postoperative pain scores and required a 47%
increase in opioid utilization. There were no differences in intrapartum pain or analgesia.
Following vaginal birth, buprenorphine maintained women had increased pain, P = 0.006, but no
increase in opioid utilization P = 0.10.20 Following cesarean delivery both pain, P = 0.009, and
opioid utilization, P = 0.004, were increased.20 Buprenorphine maintained women have similar
intrapartum pain and analgesic needs during labor but experience more postpartum pain and
require 47% more opioid analgesic following cesarean delivery.20 The data suggest that patients
can be maintained on buprenorphine throughout labor and delivery with a modest increase in
opioid analgesics available if cesarean delivery is required.20
DISCUSSION
Summary of Evidence
Three RCTs with a total of 153 patients, five case reports with a total of 104 patients, five
observational studies with a total of 173 patients, a Delphi survey, an editorial, and a clinical
outline were included in this quality improvement project. Several studies were excluded which
had an inappropriate publication date, i.e., older than 2010, wrong population, e.g., non-OUD
patients or non-surgical patients on buprenorphine, and wrong intervention, e.g., patient not on
buprenorphine for OUD. Of the fourteen articles found, two were rated as high quality, and
twelve were rated as a medium quality based on Johns Hopkins' appraisal scale. Due to larger
sample sizes, well-defined methodology and inclusion criteria, as well as rigorous statistical
methods, two of the articles met the criteria for high-quality level 1 evidence. Twelve articles
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appraised by the Johns Hopkins' tool, as medium-quality level 1 evidence had small sample sizes
or mediocre defined inclusion criteria and methodology.
Of the fourteen articles analyzed all recommended continuing buprenorphine throughout
the perioperative period. The articles suggest that potential complications can arise when
buprenorphine is discontinued for more than a few days, and patients are placed on full agonist
opioids before surgery.17 According to Scholzen et al. it is important to recall that buprenorphine
possesses significant agonist activity. 19 Therefore, if the patients discontinue buprenorphine
therapy preoperatively, patients have been found to suffer through increased pain and require
significantly more opioids in the first 24 hours after surgery than those who are continued on
their buprenorphine preoperatively.
In the five case reports, every patient whose buprenorphine was discontinued experienced
poorly controlled pain was taking 16 mg SL daily or greater preoperatively. Pain was
successfully controlled in all but one of the patients taking 16 mg buprenorphine SL daily or
greater who continued buprenorphine. The articles reviewed suggest that the traditionally
conservative approach of discontinuing and reducing opioids perioperatively may not be the
most effective way to manage patients with OUD. Evidence suggests that the continuation of
buprenorphine may offer the most effective analgesia while maintaining opioid-replacement
therapy. Hansen et al. and Macintyre et al. directly address this theory with the cohort study
performed. The evidence suggested that pain control was easier to achieve with greater
functional recovery when buprenorphine was continued throughout the perioperative period.13,21
Although there is no consensus in the literature about managing acute pain in patients
taking buprenorphine, according to Chern et al there are three alternative options when regional
anesthesia is contraindicated or not considered in this case. The first option is to continue
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buprenorphine and supplement with additional buprenorphine if needed. Rising the dose of
buprenorphine is an option, mainly when used in the treatment of OUD to avoid relapse of
opioid use. The ceiling effect is a concern when increasing the dose of buprenorphine due to
inadequate pain management; however, 1 case study reports adequate pain control. The next
alternative is to proceed preoperatively with buprenorphine; however, conventional opioids can
be substituted if there is insufficient pain relief by additional buprenorphine. The risk is that
substantial doses will be necessary to counteract the high receptor affinity and the partial
antagonist effects of buprenorphine. Sedation and respiratory depression can become significant
concerns at those doses, and higher levels of monitoring postoperatively may be required.
Finally, buprenorphine can be converted to a traditional opioid preoperatively with the
continuation of buprenorphine following the acute perioperative period. While there is no
antagonist effect to overcome, large doses of opioids may still be required as described in this
case since these patients may have significant tolerance.
According to Goel et al, it is almost always appropriate to continue buprenorphine at the
preoperative dose. Additionally, it is rarely appropriate to reduce the buprenorphine dose. Some
of Goel's perioperative interventions included: initiate adjunct analgesics including NSAIDs,
acetaminophen, ketamine, gabapentin/pregabalin, dexmedetomidine, and lidocaine in the
perioperative period for analgesia; discharge the patient on same dose of buprenorphine;
discharge the patient on some full mu agonist for analgesia, and initiate outpatient buprenorphine
provider involvement in the perioperative period. A summary of significant existing
perioperative recommendations of patients on buprenorphine are listed below:

37
Figure 4. Approaches to Manage Patients Perioperatively on Buprenorphine.19
Anderson et al
• Where moderate-to severe pain is expected, cancel surgery such that
buprenorphine is weaned off before surgery and short-acting opioids are used to
replace it.
• A plan for follow-up and reinstitution of therapy should be established.
• Anticipate patient’s opioids requirements will be similar to an opioid-tolerant
patient.
• Consider adjunctsd NSAIDs, membrane stabilisers, acetaminophen, local
anaesthetics, regional anaesthetic techniques.
Lembke et al
• Continue buprenorphine in the perioperative period for patients taking 12 mg SL or
less.
• Taper buprenorphine to 12 mg SL 2-3 days before operation.
• Multimodal analgesia, regional techniques where possible.
• Higher than normal doses of opioids to treat pain for 2-4 days post-surgery.
Scholzen et al
• In all patients on buprenorphine, discontinuing buprenorphine led to at least a 50%
relapse in opioid use.
• Continue buprenophine in the perioperative period.
• Maximizing perioperative multimodal analgesia and regional anesthesia techniques
may offer perioperative benefits.
Limitations of the Quality Improvement Project
The quality of evidence regarding perioperative management of patients on
buprenorphine is weak. The number of studies is limited, and few directly evaluate the
continuation versus discontinuation of buprenorphine. Of the observational studies, including
matched cohort, prospective cohort, and retrospective cohort, that included patients on
buprenorphine as part of the outcomes, four met the inclusion criteria. Many of the articles
reported variables such as pain levels, buprenorphine dose, and perioperative buprenorphine
continuation. Differentiation amongst different formulas of buprenorphine was not separated
during case reports or RCTs. Only three studies, all case reports included relapse rates, with one
extending beyond the three-week time point.
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An evidence-based guideline for perioperative management for patients on chronic
buprenorphine is needed.10 However, additional research needs to be conducted to determine the
best perioperative regimen for acute pain management in patients with OUD. Regardless of
choice, multimodal analgesia should be used when possible, and the anesthesiologist must
anticipate the need for large doses of traditional opioids and detailed preoperative discussion
with patients is needed.
The existing guidelines cited in the systematic review are mainly driven by expert
opinion with little reference to peer-reviewed primary evidence.22 Potential weakness in the
existing guidelines includes the recommendation to transition patients to short-acting opioids
before surgery. Evidence to the contrary shows lower relapse rates in the OUD patient
population that are maintained on buprenorphine. Other guidelines disagree with this practice
and do not recommend replacing buprenorphine with full mu agonists in the perioperative
period.
Overall, the current evidence for continuing or discontinuing buprenorphine
perioperatively is limited.22 To better manage patients with OUD, providers caring for patients
on buprenorphine in the perioperative setting need to incorporate harm reduction into goal
setting and decisions. In every case, connecting with outpatient primary care physicians and
addiction specialists during the preoperative period is advised to ensure proper follow-up for
these patients. During the preoperative assessment, attention should be paid to each patient's
buprenorphine dose, indication, and relapse risk.
Recommendations for Future Research
To help manage patients presenting to surgery with OUD taking buprenorphine, further
research must focus on managing OUD patients during the perioperative period. Also, largerscale RCTs with larger sample sizes in multi-centers to make the results more evident. Future
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research on perioperative buprenorphine management should separate comparisons of pain
scores according to transdermal or SL buprenorphine. Data suggested the discontinuation of
transdermal buprenorphine is less critical to its continuation, so the analyses of the articles were
focused on SL buprenorphine.11
Future studies should recognize the importance of differentiating the designation of a
history of OUD from current OUD.11 As with any retrospective analysis, the studies had poor
control over the exposure factor in terms of each patient's buprenorphine regimen. Of the
fourteen articles, only three included long-term follow-up, relapse rates, or mortality. Further
work includes performing a comprehensive retrospective cohort study on the buprenorphine
patients who were managed after implementing a standardized checklist and extending into a
longitudinal study to monitor for long-term rates of addiction relapse, including long-term
morbidity and mortality. Future studies should require standardized reporting of median doses,
details on the route of delivery, dosing schedules, any dosing changes, and addiction relapse
rates for patients with OUD on buprenorphine. Future studies should be designed to study a
single surgical type with a standardized anesthetic management protocol to control regional
anesthesia's influence on PACU pain scores and opioid administration.15 Ultimately, the
population of patients who use buprenorphine for OUD is heterogeneous and is not isolated to a
particular surgical subtype. The finding of buprenorphine continuation is associated with
adequate pain control across surgical types has true practice generalizability.15
Although some recommendations for treating acute pain in opioid-dependent patients
have already been published, due to a lack of RCTs, most of the evidence has been collected in
case reports, retrospective studies, and expert opinions. These emphasize the importance of
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continuing buprenorphine maintenance therapy as a foundation. A prospective trial where
patients are randomized to continue or stop buprenorphine should be conducted in the future.15
Recommendations for Practice Presented in an Algorithm
Preoperatively, the perioperative buprenorphine policy is dose-dependent for patients
taking ≤10 mg versus >10 mg of buprenorphine.11 According to Li et al, patients on a baseline
dose of ≤10 mg are required to meet the following three guidelines: buprenorphine should be
continued, the buprenorphine prescriber should be made aware of the upcoming surgery, and a
consult to the Pain Service should be placed via the preoperative order set. The above guidelines
also apply to patients on a baseline dose of >10 mg.11 However, for scheduled procedures with
an anticipated high degree of postsurgical pain, the guideline is to consider tapering to an 8mg
dose in conjunction with the buprenorphine prescriber at least 72 hours before surgery or
delaying the surgery if it is elective. Quaye et al suggested the 8mg threshold.11
Regarding intraoperative considerations, all patients are instructed to take buprenorphine
or arrive on the day of surgery with the patch on with plans to have the patch reapplied
immediately postoperatively. Preoperatively, patients also receive nonopioid pain medications,
specifically acetaminophen, gabapentin, and NSAIDs. Furthermore, regional or neuraxial
anesthesia is employed if possible; otherwise, patients should receive an infusion of ketamine
and lidocaine. Finally, at the anesthesia provider's discretion, patients should be induced with an
opioid of the anesthesia provider's choice before intubation; meanwhile, the dose of opioid
required to achieve a decrease in the respiratory rate is reported to the acute pain service.11
Provided below in Figure 3 is an algorithm based on the evidence found in this systematic
review, other current literature, and guidelines suggested for anesthesia providers' clinical
practice.
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Figure 5. Quate and Lembke et al Algorithm for Perioperative Buprenorphine Management.11
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CONCLUSION
Buprenorphine is a semisynthetic opioid agonist-antagonist used primarily to treat
OUD.10 Its pharmacokinetic and pharmacodynamic properties make it an attractive drug for this
purpose. It has a high affinity for the mu and kappa receptors and very slow dissociation, giving
it an extended duration of action and limiting the opioid "high" produced by a pure mu agonist
methadone. There is a ceiling effect at higher doses, reducing the abuse potential and minimizing
respiratory depression. It also attenuates other opioid agonists' effect, decreasing the euphoria
and efficacy of concurrently administered opioids.
There is no consensus of the management of buprenorphine, however, the
recommendation is to continue buprenorphine during the perioperative period. The patient's
outpatient buprenorphine provider should be engaged before surgery and as soon as is feasible
after discharge.8 The perioperative physicians should engage the patient early to outline
strategies, manage expectations about the perioperative course, and explain the importance of
treatment retention.8
IMPLEMENTATION
Setting and Participants
The setting will take place through an online survey and a PowerPoint educational
module with the members of the Anesthesia Department from Anesco Anesthesia Services at
Broward General Hospital. The preliminary study will include anesthesia providers such as
Certified Registered Nurse Anesthetist (CRNAs) and Anesthesiologists. The participation will be
based on individuals who were forwarded within the email list provided by Broward General
Hospital and will be asked to provide feedback regarding the educational module's anesthesia
providers' experience. The anticipated sample size will be between 15-20 participants.
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Recruitment
The target population consisted of CRNAs and Anesthesiologists who have taken care of
patients throughout the perioperative period on buprenorphine with OUD. Participants were
identified through an email list provided by Broward General Hospital. The anesthesia providers
within the email list were emailed an invitation to participate in the educational module.
Description of Approach and Project Procedures
The primary methodology of the proposed project is to administer an online Zoom
educational module to providers that focuses on perioperative management of patients with OUD
who take buprenorphine. The project will be implemented by conducting an online preassessment test that will assess the anesthesia providers knowledge about managing a patient
with OUD on buprenorphine during the perioperative period. The existing knowledge and
understanding of the anesthesia provider will be defined using a pre-evaluation tool that will
influence the intervention's information and determine the content or subject matter of the
intervention.
The second phase will include a Zoom educational PowerPoint. The primary means of
learning will be through a voiceover PowerPoint presentation with information regarding the
management of patients with OUD on buprenorphine in the perioperative period. Anesthesia
providers' education is essential in bridging existing gaps in knowledge and supporting the need
for additional tools to ensure patients on buprenorphine are provided evidence-based care during
the perioperative period. Current education is limited in the perioperative patient taking
buprenorphine for OUD.4 Anesthesia providers must have knowledge that will benefit patients
with OUD on buprenorphine to ensure proper pain management postoperatively and relapse
prevention. The delivery of the presentation will offer insight for providers regarding the
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importance of continuing buprenorphine during the perioperative period in order to prevent
relapse and control postoperative pain in patients with OUD. The empirical evidence supports an
evidence-based project with comprehensive information regarding continuing buprenorphine
throughout the perioperative period and its benefits for OUD patients. A checklist will be
provided within the education module on how to manage patients with OUD taking
buprenorphine during the perioperative period.
The third phase of the project will involve an online post-assessment test to identify
the anesthesia providers learned knowledge and perception to the intervention and the contents
that were delivered. This information will provide greater feedback regarding the impact of the
educational intervention and will determine how to best move forward in expanding the use of a
perioperative checklist for patients taking buprenorphine with OUD. The pre/post-testing will
provide relevant information regarding the effectiveness of continuing buprenorphine during the
perioperative period and improve patient satisfaction postoperatively. At the end of the
educational tool, feedback will also demonstrate if the perioperative checklist will improve
anesthesia providers' knowledge and if any changes are necessary for the future so that other
anesthesia providers will benefit from the program in the future.
Protection of Human Subjects
Anesthesia providers participating in the survey remained anonymous, and the data was
secured by using unique code identifiers. The digital data collected from the pre-test and posttest were protected by a laptop password and spyware. Using laptop passwords and spyware, this
ensured the safety of the data. There are no perceived risks to the study as it only requires the
time spent by each anesthesia provider in the educational module which took less than 20
minutes to complete.
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Data collection and analysis
For the study, the primary instruments included preassessment and post-assessment
testing applications to determine the effects of the educational module. Both tests will be
conducted using surveys utilizing Qualtrics that will determine if participants have an
understanding of managing surgical patients with OUD taking buprenorphine during the
perioperative period. The survey consisted of 15 questions that focus on knowledge and practice.
The pre-test survey will gauge baseline knowledge. In contrast, the post-test survey will
determine the participants knowledge from the educational module and application of knowledge
gained to professional practice. The data collected will be confidential, and no subject identifiers
will be recorded during any component of the study.
Data Management and Measure
The investigator for the project will be the DNP student responsible for obtaining the
members of the Anesthesia Department at Broward General Hospital via email list for
administration of the pre and post survey and Zoom educational module. Each question will be
measured, and the responses recorded to identify the knowledge base before and after the
educational module. No personal identifiers will be recorded for each of the study participants so
that confidentiality will be protected. The impact of the educational module will be based upon
the results of the pre-and post-test survey instruments. Through the statistical analysis, the study
results will likely identify patterns that will be used to determine the effectiveness of the
educational module and if the module will improve anesthesia providers' knowledge. The coinvestigator will store the data collected in a password-protected laptop computer.
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IMPLEMENTATION RESULTS
Pre/Post-Test Demographics
The pre-test demographics are shown in Table 4., shown below.
Pre-Test Participants Demographics
Demographic
Total Participants
Gender
Male
Female
Age
25-35
36-45
46-55
56-66
Ethnicity
Hispanic
Caucasian
African American
Asian
Other
Position/Title
CRNA
MD/DO
Years of Experience
Less than 1 year
1 to 5 years
6 to 10 years
More than 10 years

n (%)
5 (100%)
1 (25%)
4 (75%)
3 (60%)
0 (0%)
0 (0%)
2 (40%)
1 (20%)
3 (60%)
0 (0%)
0 (0%)
1 (20%)
5 (100%)
0 (0%)
1 (20%)
2 (40%)
0 (0%)
2 (40%)

There were 5 participants in the pre-test demographics. The majority of the participants
were female (n=4, 75%) instead of male (n=1, 25%). There were also a range of ethnicities
represented: Caucasian (n=3, 60%), Hispanic (n=1, 20%), and other (n=1, 20%). Information
was obtained regarding the participant's role at the clinic. It was found that all participants were
CRNAs. The participants were questioned about the length of time practicing, finding that the
practice period ranged: less than one year (n=1, 20%), 1 to 5 years (n=2, 40%), and more than 10
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years (n=2, 40%). The participants consisted of DNP-prepared CRNAs (n=3, 60%) and Master
level prepared CRNAS (n=2, 40%).
Pre-Test Confidence in Management of Surgical Patients with Opioid Addiction on
Buprenorphine
The pre-test contained information regarding the perioperative management of surgical
patients with opioid addiction on buprenorphine. The majority of participants (n=3, 60%) did not
feel confident managing surgical patients on buprenorphine with opioid use disorder. The survey
concluded that most participants (n=4, 80%) did not have patients who took buprenorphine often.
In the pre-test, the participants (n=4, 80%) reported that a checklist for surgical patients with
opioid addiction taking buprenorphine would somewhat unlikely be implemented.
Pre-Test Identification of Current Knowledge about Perioperative Management of
Surgical Patients with Opioid Addiction on Buprenorphine
The survey focuses on identifying the benefits of a perioperative checklist for patients
with opioid addiction taking buprenorphine. The participants know the mechanism of action of
buprenorphine; the question was correctly answered by four participants (n=4, 80%). When
asked about the withdrawal effects of buprenorphine, all five participants answered the questions
correctly (n=5, 100%). All participants (n=5, 100%) answered how buprenorphine is provided
for addiction maintenance treatment. The participant's scores improved in the post-test when
asked about questions pertaining to perioperative management of surgical patients taking
buprenorphine (n=5, 100%). The participants were asked questions involving the
pharmacokinetics and pharmacodynamics of buprenorphine, scores generally improved when
comparing pre- and post- test. Table 4 shows the difference in responses from the pre- to posttest.
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Table 5. Difference in Pre- and Post-Test Knowledge
Questions
What is TRUE about opioid use disorder (OUD) and
buprenorphine?
What are the MAIN uses for buprenorphine?
What is the method of action of buprenorphine?
The affinity of buprenorphine results in?
The goals of buprenorphine maintenance treatment include:
Which statement is TRUE about withdrawal from buprenorphine?
If the patient continued buprenorphine perioperatively, what are
some of the unique considerations that apply to the patient?
Compared with conventional opioids, the pharmacodynamics of
buprenorphine ___.
Which of the following is TRUE regarding tapering and
discontinuing use of buprenorphine before surgery?
If the patient DID NOT continue buprenorphine preoperatively,
what are some of the unique considerations that apply to the
patient?
How does buprenorphine provide addiction maintenance treatment?
What statement is TRUE about buprenorphine during the
perioperative period?

Pretest
80%

Posttest Difference
100%
20%

80%
80%
80%
80%

80%
80%
80%
80%

0%
0%
0%
0%

100% 100%
40% 60%

0%
20%

40%

60%

20%

40%

100%

60%

40%

100%

60%

100% 100%
100% 100%

0%
0%

After the Zoom PowerPoint presentation, scores increased on the post-test from the
baseline pre-test scores. The majority of participants improved knowledge about perioperative
management of patients on buprenorphine (n=3, 60%). When asked questions about managing
patients on buprenorphine perioperatively and unique considerations of buprenorphine, only one
person (n=1, 20%) improved the post-test score. However, there was an (n=3, 60%) increase
post-test in participants that were able to identify true statements about tapering and
discontinuing use of buprenorphine before surgery. Lastly, all participants answered how
buprenorphine provides addiction maintenance treatment (n=5, 100%).
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Post-Test Confidence in Management of Surgical Patients with Opioid Addiction on
Buprenorphine
Participants were very confident (n=3, 60%) or somewhat confident (n=2, 40%) in
managing a patient on buprenorphine with OUD after completing the educational module. When
asked how often the participant had a patient in the perioperative period who takes
buprenorphine, the majority selected rarely (n=4, 80%) compared to sometimes (n=1, 20%).
Table 6. Implementation of a perioperative checklist for surgical patients with opioid
addiction taking buprenorphine

How likely are you to implement a perioperative
checklist for surgical patients with opioid
addiction taking buprenorphine?

Pre-test
20%

Post-test
100%

Difference
80%

Table 5 shows the educational module changes in participants' perspectives on
implementing a perioperative checklist when comparing the pre-test and post-test scores. The
results suggest that the narrated PowerPoint presentation provided the necessary educational
information, leading CRNAs to feel inclined to incorporate a perioperative checklist to manage
surgical patients with OUD on buprenorphine.
Summary
Overall, the results reflected an improvement in knowledge based on the pre-test and
post-test scores. Knowledge showed an average gain of (25%). In addition, the post-test
demonstrated that participants are most likely (n=4, 80%) or somewhat likely (n=2, 20%) to
implement a perioperative checklist for surgical patients with opioid addiction taking
buprenorphine.
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Summary
120
100
80
60
40
20
0
Knowledge

Implementation of a perioperative checklist for
surgical patients with opioid addiction taking
buprenorphine
Pre-test

Post-test

IMPLEMENTATION DISCUSSION
Limitations
Limitations of the study include a small sample size; the survey was emailed to the
members of the Anesthesia Department at Broward General Hospital. There were 46 emails on
the list; however, only five people completed the survey. A larger sample size is preferred to
enhance the study's findings and offer a sample size that mirrors Broward Health Hospital's
anesthesia practitioners. The survey link, which included a pre-test, a narrated PowerPoint
presentation, and a post-test, was available online for two weeks; extending the time frame may
have resulted in more replies. Finally, the project was completed entirely online, preventing it
from being delivered through other means.
Future Implications for Anesthesia Practice
The literature demonstrated that a checklist for surgical patients taking buprenorphine
will likely expand the knowledge base of the anesthesia providers and will demonstrate the
importance of developing a meaningful strategy for improving the care for surgical patients
taking buprenorphine. and in providing the best possible resources to treat patients effectively.
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The anesthesia providers knowledge will improve, when an evidence-based checklist is
provided. A perioperative checklist will improve the outcomes of surgical patients and ensure the
best possible postoperative pain management will be provided to patients on buprenorphine. The
quality improvement project showed that the intervention was effective in increasing healthcare
providers knowledge and confidence on perioperative management of surgical patients with
OUD taking buprenorphine.
During the perioperative period, there are no policies, or checklists for managing surgical
patients on buprenorphine, which presents an opportunity to close the gap between
recommendation of care and actual care delivery. Implementing the evidence-based checklist for
the perioperative management of surgical patients with opioid addiction on buprenorphine will
improve the quality and standard of care for OUD patients on buprenorphine. The
implementation of a checklist is essential for anesthesia to help improve outcomes and relapse
prevention for surgical patients with OUD on buprenorphine.
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Appendix B: Matrix Table
Author (Year) &
Level of Evidence

Indications
for
Buprenorphin
e use

Jonan et al.
(2018)

Chronic pain
or OUD

Study type/
Sample size

Chronic pain

Level 5
Quality A

Vaginal mesh
removal and
cystoscopy
X2

Both methods were
conducted,

Sample Size:
1

Hansen et al.
(2016)
Level 3
Quality B

Study group
(patients with a
history of
OUD)
compared to a
control group
(patients
without a
history of
OUD)

Independent
Variables

Dependent
Variables

Recommendations for
preoperative
management of
buprenorphine was
based on urgency and
type of surgical
procedure.

Level 4 Quality A

Chern et al.
(2013)

Findings: Was
buprenorphine
continued
perioperatively or
discontinued

Total hip (n
= 8) and
knee (n = 9)
arthroplasty,
continuing
Buprenorphi
ne /naloxone

Buprenorphine/naloxo
ne was continued in
the patients with a
history of OUD.

Analgesia success

Success of
deterrence
against
opioid abuse

Guidelines
provided

Poorly controlled
pain

High risk of a
relapse if
buprenorphin
e is held for
an extended
period prior
to the
procedure.

Yes

Non-reported

Yes

Relapse rate
of heroin
addiction has
been shown
up to 50%.

No

Independent
variable: IV1:
The patient
withheld from
taking
buprenorphine
for the first
surgery. IV2:
The patient
continued
buprenorphine
throughout the
perioperative
period.

Dependent
variable: DV1:
The patient
was in severe
pain in the
postoperative
period when
buprenorphine
was continued
during the
perioperative
period. DV2:
When the
patient
withheld
buprenorphine
during the
perioperative
period, the
patient
reported
adequate pain
control in the
postoperative
period.

Buprenorphine was
discontinued five
days before surgery
and the patient was
switched to
hydromorphone 4
mg PO q4-6 hours.
The patient
experience
"unbearable" pain
8/10.

Independent
Variables:
IV1: Patients
who take
buprenorphine/
naloxone
compared to
those who do
not take
buprenorphine/
naloxone.

Dependent
Variables:
DV1: In the
study group
(those taking
buprenorphine/
naloxone) two
patients
developed
deep
infections. In
the control
group (those
not taking
buprenorphine/
naloxone) one
patient
developed a
deep infection.
DV2: A
change in
morphine
dosing at the

There was no
significant
difference in pain
scores between
groups studied

Patient experience
poorly controlled
pain when
buprenorphine was
continued
perioperatively.

Conclusion

Although there is no
consensus in the
literature as to how to
best manage acute pain
in these patients, there
are three alternative
options when regional
anesthesia is
contraindicated or not
considered as in this
case. The first option is
to continue the
baseline regimen and
supplement with
additional
buprenorphine. The
second option is to
continue the
buprenorphine
preoperatively;
however, if pain
control is inadequate
with additional
buprenorphine,
traditional opioids will
need to be added.
Lastly, the
buprenorphine can be
converted to a
traditional opioid
preoperatively with
resumption of
buprenorphine
following the acute
perioperative period.
The patients took
buprenorphine/naloxon
e preoperatively can
achieve adequate pain
control and successful
clinical outcome after
surgery. Similar
experiences with
controlled groups
compared to the study
group were identified.
Equivalent pain
control and successful
clinical outcome at 1
year can be achieved in
patients who use
methadone or
buprenorphine/naloxon
e preoperatively.
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time of
discharge
decreased in
the study
group (-203.5)
and increased
in the control
group (84.3).

Kornfeld et al.
(2010)

Chronic pain
or OUD

Five patients
who
underwent
seven major
surgical
procedures
including
colectomy,
total knee
replacement,
small bowel
resection and
mastectomy.

There were no
interruptions of daily
buprenorphine therapy.

Independent
Variable: IV1:
Increased dose
of
buprenorphine
for
postoperatively
surgery vs
sample dose
buprenorphine
a
preoperatively

OUD

22 patients,
Any surgery,
taking
buprenorphin
e or
methadone.

Partial: buprenorphine
continued POD 0 in
14/22 patients (64%)
and POD 1 in 11/22
patients (50%).

Independent
variable:
methadone
opioid
substitution
therapy
(MOST)versus
buprenorphine
opioid
substitution
therapy
(BOST)

Level 5
Quality A

Macintyr et al.
(2013)
Level 4
Quality B

Dependent
Variable:
DV1: For
surgery 2
During the
patient’s
hospital stay
postoperatively
buprenorphine
was continued,
and the patient
was discharged
on 16 mg of
buprenorphine
and on oral
hydromorphon
e for
breakthrough
pain. DV2: For
same patient
(surgery 3)
sublingual
buprenorphine
was not given
during this
brief
hospitalization
but was
restarted
without
difficulty at
discharge at
the
preoperative
dose. Pain was
well managed
however,
patient had
multimodal
pain
management
including an
epidural.
Dependent
variable: DV1:
PCA
morphine,
DV2: pain
scores, DV3:
cessation of
buprenorphine,
DV4: First 24hour analgesic
doses, efficacy
and adverse
effects

All had successful
analgesia reported.

Non-reported

No,
however,
emphasized
the need for
perioperative
guidelines.

Potential
complications arise
when buprenorphine is
discontinued for more
than a few days and
patients are placed on
full agonist opioids
before surgery, making
it difficult to reconvert
to buprenorphine. The
robust effectiveness of
full agonist opioids in
patients stabilized on
buprenorphine
undergoing major
surgery supports the
strategy of
uninterrupted
buprenorphine
treatment in these
patients.

Well controlled
pain, no significant
differences between
groups or between
continuation
without stopping.

Non-reported

No,
suggested
continuing
buprenorph
ine
perioperativ
ely

In summary, the audit
showed that the
efficacy and safety of
PCA opioids
prescribed for the
management of
postoperative pain is
similar for BOST and
MOST patients.
Importantly, PCA
opioid requirements
were less in patients in
whom BOST was
continued
perioperatively
compared with those
patients whose regular
BOST was ceased, and
therefore BOST should
not be withheld in
patients undergoing
surgery. That is,
administration of
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Quaye et al.
(2020)

OUD

55 patients,
who had
surgery from
MarchOctober
2018. Minor
procedures
such as
colonoscopie
s and
endoscopies
were
excluded.

Partial: 38 continued
buprenorphine versus
17 held buprenorphine

Independent
variable:
Patients either
abstaining
from
buprenorphine
perioperatively
of continuing.

Dependent
variable:
History of
OUD.

The number of
opioid prescriptions
dispensed was
significantly higher
with buprenorphine
discontinuation.
PACU pain scores
were higher with
buprenorphine
discontinuation.

Non-reported

No, suggest
continuing
buprenorph
ine
perioperativ
ely

OUD

Tricuspid and
Aortic valve
repair

Discontinued and
restarted
postoperatively; timing
of change was not
reported.

Independent
variables:
OUD patient
took
buprenorphine
for chronic
pain.

Dependent
Variable:
discontinue of
buprenorphine
before surgery
and restarted
after the
procedure was
completed

Well controlled
pain

Six months
after surgery
refrained
from opioids

No

Continued
buprenorphine by 50%
postoperatively, with
subsequent tapering to
0 mg before discharge.

Independent
variable: IV1
Continued
regular dose of
Suboxone 16
mg twice a day

Dependent
variable: DV2
high
postoperative
pain scores.

Pain was poorly
controlled;
Improved after
postoperative
decrease

Abstained
from opioids
at three week
follow-up

No

Level 2
Quality B

Hassamal et al.
(2017)
Level 5
Quality A

Huang et al.
(2014)
Level 5
Quality B

Sample Size:
1

Chronic pain

Clagett
window
closure
Sample size:
1

buprenorphine in
BOST patients does
not adversely affect
acute pain
management using full
agonist opioids after
surgery.
Patients who continued
buprenorphine had a
significant reduction in
opioid prescriptions
filled and PACU pain
scores in patients than
patients who held
buprenorphine
perioperatively.
Evidence was provided
to support that
buprenorphine can be
continued
perioperatively, and
that continuation is
associated with
decreased
postoperative pain and
decreased outpatient
opioid dispensing. The
results contribute to
the existing literature
supporting the
perioperative
continuation of
buprenorphine.
In summary, initiating
buprenorphine in the
acute medical setting
along with continued
outpatient addiction
treatment is an
effective yet
underutilized strategy.
Initiating MAT in the
hospital setting
provides an
opportunity to engage
high-risk patients in
substance abuse
treatment, decrease
recidivism, and
subsequently improve
patient outcomes and
decrease health care
costs. An inpatient
setting offers the
advantage of close
monitoring and
supervision during a
critical period of
change that may not be
available in an
outpatient setting.
Therefore,
practitioners should
not be hesitant to start
buprenorphine in
acutely ill patients with
an opioid use disorder.
In a chronic pain
patient continued on
buprenorphine/naloxon
e perioperatively,
significant
improvement in
postoperative pain
control was observed
following tapered
doses. Eventually, the
use of
buprenorphine/naloxon
e was discontinued.
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Martine et al.
(2019)

OUD

Level 5
Quality A

Various
surgeries and
type of
anesthesia
included in
the study.

19 patients continued
sublingualbuprenorphine, 13
discontinued
sublingualbuprenorphine 1 to 30
days before surgery.

Independent
Variable: IV1
Various types
of anesthesia
for patients
taking
sublingualbuprenorphine
IV2
Continuing vs
discontinuing
sublingualbuprenorphine
prior to
surgery

Dependent
Variable: Use
of opioids
increasing in
PACU in
patients with
long-term
treatment of
sublingualbuprenorphine

Patients who
received long-term
treatment with
sublingualbuprenorphine had
high opioid
requirements
through POD1,
regardless
of type of
anesthesia used or
whether sublingualbuprenorphine was
preoperatively
continued or
discontinued.

Recommendations to
continue
buprenorphine in the
peri-operative period.

Independent
variable:
Management
of patients on
buprenorphine.

Non-reported

Continued
perioperatively

Independent
variable: V1:
Intrapartum
and
postpartum
pain
management
for women on
buprenorphine
IV2: Pain
management
for patients
with OUD
taking
buprenorphine
compared to
non-OUD
patients

Dependent
variable:
Developing
guidelines and
a set of
recommendati
ons for the
perioperative
management
of patients
taking
buprenorphine
Dependent
variable: DV1:
c-section DV2:
vaginal
delivery DV3:
continued
buprenorphine
preoperatively
pre-operatively
DV4: pain
management
techniques
(epidural)

Sample size:
32

Goul et al.
(2019)

Chronic pain
or OUD

Level 4
Quality A

Meyer et al.
(2010)
Level 2
Quality B

OUD

Vaginal (n =
44) and
Cesarean (n
= 19)
delivery
taking
buprenorphin
e

Pain was well
controlled,
Significantly higher
pain scores in study
group versus
controls postpartum

The use of
opioids
increased
substantially
after
discharge
from the
PACU, and
by 24 hours
after PACU
discharge, no
differences in
opioid
requirements
were noted
between
patients who
underwent
surgical
procedures
with general
anesthesia
only versus
combined
general/regio
nal
anesthesia.
Non-reported

No

Regardless of the type
of anesthesia used,
physicians treating
patients with
sublingualbuprenorphine must be
prepared to administer
large doses of opioids
during the early
postoperative period.
No difference in opioid
requirements was
noted between patients
who perioperatively
stopped sublingualbuprenorphine versus
those who sublingualbuprenorphine.

Yes,
several
guidelines
from
difference
authors
were
included in
the article.

Goel et al. identifies
that long-term
treatment retention,
mortality, and
morbidity are essential
when deciding to stop
or continue
buprenorphine during
the perioperative
period.

Non-released

No

Buprenorphine
maintained women
have similar
intrapartum pain and
analgesic needs during
labor but experience
more postpartum pain
and require 47% more
opioid analgesic
following cesarean
delivery.
The data suggest that
patients can be
maintained on
buprenorphine
throughout labor and
delivery with a modest
increase in opioid
analgesics available if
cesarean delivery is
required.
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Appendix C
Proposed Method for Data Collection Pretest and Posttest Questionnaire

Pretest and Posttest Questionnaire:
A Quality Improvement Checklist for the Perioperative Management of Surgical Patients
with Opioid Addiction on Buprenorphine

INTRODUCTION
The primary aim of this QI project is to improve the knowledge of anesthesia providers in
order to improve perioperative management of patients taking buprenorphine for opioid
addiction.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or select all that apply. These questions are meant to measure knowledge and
perceptions on identification, management, and patient education on management of
buprenorphine throughout the perioperative period.
PERSONAL INFORMATION
1. Gender: Male

Female

Other

2. Age: ______
3. Ethnicity:
Hispanic

Caucasian

African American

Asian

Other

4. Number of years of experience:
Less than1 year

1-5 years

6-10 years

more than 10 years

5. Type of anesthesia provider: _________________________________
6. Level of Education: Associates

Bachelors

Masters

DNP

PhD

M.D.
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QUESTIONNAIRE
1) How confident do you feel managing a patient in the perioperative period on
buprenorphine with opioid use disorder (OUD)?
a. Very confident
b. Somewhat confident
c. Somewhat unconfident
d. Very unconfident
2) How often do you have a patient in the perioperative period who takes buprenorphine?
a. Often
b. Sometimes
c. Rarely
d. Never
3) As the anesthesia provider, how likely are you to implement a periopertive checklist for
surgical patients with opioid addiction taking buprenorphine?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
4) What is TRUE about opioid use disorder (OUD) and buprenorphine?
a. Opioid Use Disorder is often treated with psychological interventions and
medications such as buprenorphine.
b. Opioid use disorder patients are on drugs that make it challenging to manage pain
in the perioperative period, including buprenorphine.
c. The structure of buprenorphine makes it an appealing selection for managing
chronic pain and opioid use disorder.
d. All the above
5) What are the MAIN uses for buprenorphine?
a. Analgesia
b. Opioid withdrawal
c. Addiction maintenance treatment
d. All the above
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CORRECT ANSWER: D.
6) What is the method of action of buprenorphine?
a. Partial agonist at Mu-opioid receptors, antagonist at Kappa-opioid receptors
b. Agonist at Mu-opioid receptors, partial agonist at Kappa-opioid receptors
c. Partial antagonist at Mu-opioid receptors, antagonist at Kappa-opioid receptors
d. Partial antagonist at Mu-opioid receptors, agonist at Kappa-opioid receptors
CORRECT ANSWER: a.
7) The affinity of buprenorphine results in:
a. A very strong bond to the opioid receptor.
b. Partial activation of mu receptor.
c.

Can precipitate withdrawal if full agonist on board.

d. All the above
CORRECT ANSWER: d.
8) The goals of buprenorphine maintenance treatment include:
A. Discontinue or markedly reduced use of other opioids
B. Persistent craving
C. Persistent withdrawal symptoms
D. The expectation of sedation
CORRECT ANSWER: a.
9) Which statement is TRUE about withdrawal from buprenorphine?
a. There is no known withdrawal syndrome when stopping buprenorphine if it has
been taken sublingually.
b. Withdrawal from buprenorphine maintenance is more severe than withdrawal
from a full agonist like methadone.
c. The time before withdrawal sets in is longer with physical dependence on
buprenorphine than with physical dependence on full opioid agonists.
CORRECT ANSWER: C. The time before withdrawal sets in is longer with physical dependence
on buprenorphine than with physical dependence on full opioid agonists.
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10) If the patient continued buprenorphine perioperatively, what are some of the unique
considerations that apply to the patient?
a. The surgeon should contact the physician prescribing buprenorphine and ensure
that the patient is aware of the surgery
b. Continue the buprenorphine for postoperative pain
c. Do NOT routinely prescribe supplemental opioids
d. All the above
CORRECT ANSWER: D.
11) Compared with conventional opioids, the pharmacodynamics of buprenorphine ___.
a. Dissociates more slowly from the μ-OR, resulting in prolonged pain relief and less
potential for withdrawal
b. Blocks OR-like-1 receptors, slowing the development of tolerance to analgesic effects
and reducing the potential for misuse
c. Blocks δ-OR and κ-OR, making it less likely to induce sedation, dysphoria,
constipation, and hyperalgesia
d. All of the above
CORRECT ANSWER: D. all of the above
12) Which of the following is TRUE regarding tapering and discontinuing use of
buprenorphine before surgery?
a. It is generally easier to go from 12 mg to 10 mg of buprenorphine than from 2 mg to
0 mg.
b. Most patients are ready to start tapering off of buprenorphine after they complete a
year of maintenance treatment.
c. If buprenorphine is discontinued, a taper over 48 hours is recommended
d. The risk of relapse is low if tapering off of buprenorphine is extended over a month.
CORRECT ANSWER: A. It is generally easier to go from 12 mg to 10 mg of buprenorphine
than from 2 mg to 0 mg
13) Patient Alexa, age 36, is quitting her misuse of hydrocodone plus acetaminophen before
surgery. She has had her first dose of generic, sublingual combination
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buprenorphine/naloxone to start treatment for opioid use disorder. If she is typical of
most patients, what target dose of buprenorphine will she most likely need?
a. 6 mg to 10 mg
b. 12 mg to 16 mg
c. 18 mg to 22 mg
d. 24 mg to 28 mg
CORRECT ANSWER: B. 12 mg to 16 mg
14) If the patient DID NOT continue buprenorphine preoperatively, what are some of the
unique considerations that apply to the patient.
a. If greater than five days off buprenorphine, treat with traditional opioids, may require
tolerant or highly tolerant doses
b. After postoperative pain normalizes, the patient may work with his or her physician to
reinstitute buprenorphine therapy
c. Assess the amount of time since the last dose of buprenorphine
d. All the above
CORRECT ANSWER: D.
15) How does buprenorphine provide addiction maintenance treatment?
a. It displaces some of the full agonists at mu receptors and provides a very limited
opioid effect. The patient DOES NOT experience opioid withdrawal symptoms but is
not receiving full agonist effect.
b. The patient DOES experience opioid withdrawal symptoms and is receiving full
agonist effect.
c. Buprenorphine does not provide addiction maitenace treatment
d. none of the above
CORRECT ANSWER: a.
16) What statement is TRUE about buprenorphine during the periopertive period?
a. In all patients on buprenorphine, discontinuing buprenorphine during the
perioperative period leads to at least a 50% relapse in opioid use.
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b. In all patients on buprenorphine, continuing buprenorphine during the perioperative
period leads to at least a 50% relapse in opioid use.
c. The patient does not need to plan for a follow-up regarding buprenorphine
management postoperatively.
CORRECT ANSWER: a.
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